| Löfgren’s syndrome | Non-Löfgren’s | |
| Patients n | 13 | 10 |
| Males/females n | 9/4 | 8/2 |
| Age yrs median (range) | 37 (29–56) | 48 (33–67)* |
| Current smokers/ex-smokers/never-smokers n | 3/2/8 | 1/4/5 |
| Radiographic stage 0/I/II/III/IV n | 0/10/3/0/0 | 0/2/3/2/3 |
| BAL analyses | ||
| Recovery % of instilled volume | 67 (60–72) | 59 (55–68) |
| Viability % | 94 (93–96) | 95 (93–98) |
| Total cell concentration ×106 cells·L−1 | 172 (99–248) | 160 (125–191) |
| Total cell number ×106 cells | 26 (13–38) | 23 (16–32) |
| Differential cell counts | ||
| Macrophages % | 77 (68–85) | 76 (64–86) |
| Macrophages ×106 cells·L−1 | 128 (81–174) | 124 (90–154) |
| Lymphocytes % | 23 (13–30) | 22 (13–34) |
| Lymphocytes ×106 cells·L−1 | 33 (13–66) | 27 (14–67) |
| Neutrophils % | 1.0 (0.4–1.7) | 1.6 (0.4–2.3) |
| Neutrophils ×106 cells·L−1 | 1.3 (0.9–2.9) | 2.5 (0.4–3.3) |
| Eosinophils % | 0.2 (0–0.4) | 0.4 (0.2–0.8) |
| Eosinophils ×106 cells·L−1 | 0.3 (0–0.5) | 0.6 (0.2–1.3) |
| CD4+/CD8+ T-cell ratio | 5.0 (2.5–11) | 4.5 (3.5–9.0) |
| AV2S3+ T-cells % of CD4+ T-cells | 28 (22–37) | 3.5 (2.5–6.7)*** |
| Blood AV2S3+ T-cells % of CD4+ T-cells | 4.4 (3.9–5.2) | ND |
| Pulmonary function tests | ||
| VC % pred | 96 (86–104) | 90 (78–99) |
| FEV1 % pred | 93 (76–102) | 90 (75–101) |
| DL,CO % pred | 94 (91–107)# | 82 (24–83)¶ |
Data are presented as median (interquartile range), unless otherwise stated. BAL: bronchoalveolar lavage; VC: vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; DL,CO: diffusing capacity of the lung for carbon monoxide; ND: not determined. #: n=12; ¶: n=3. *: p<0.05 by Mann–Whitney U-test; ***: p<0.001 by Mann–Whitney U-test.